MedImmune venture capital arm leads financing of cancer drug developer G1

19:20 EDT 16 Oct 2013 | SCRIP

Chapel Hill, North Carolina-based G1 is studying a treatment for myelosuppression, a side effect of chemotherapy that limits production of blood cells and platelets. The company said it plans to file an investigational new drug application with the U...

Original Article: MedImmune venture capital arm leads financing of cancer drug developer G1

NEXT ARTICLE

More From BioPortfolio on "MedImmune venture capital arm leads financing of cancer drug developer G1"

Search BioPortfolio:
Advertisement

Relevant Topic

Blood
Latest News Clinical Trials Research Drugs Reports Corporate
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...

Advertisement

Searches Linking to this Story